I. Franjkovic

Effects of common atopy-associated amino acid substitutions in the IL-4 receptor alpha chain on IL-4 induced phenotypes

I. König, A. Ziegler, H. Hackstein, 2005, Immunogenetics.

Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma

J. Briones, E. González-Barca, J. Brouwer-Visser, 2021, Blood advances.

A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma

J. Laubach, M. Liedtke, A. Chanan-Khan, 2021, Blood Cancer Journal.

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

M. Hidalgo, T. Nayak, K. Stubenrauch, 2017, Clinical Cancer Research.

An efficient strategy for gene mapping using multipoint linkage analysis: exclusion of the multiple endocrine neoplasia 2A (MEN2A) locus from chromosome 13.

K. Kidd, J. Kidd, P. Goodfellow, 1987, American journal of human genetics.

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

H. Hurwitz, J. Bendell, K. Lechner, 2019, The oncologist.

Abstract CT096: Phase 1 study of RO7119929 (TLR7 agonist prodrug) in patients (pts) with advanced primary or metastatic liver cancers

B. Sangro, T. Yau, Chia‐Chi Lin, 2023, Cancer Research.